Karyopharm Therapeutics Stock Forecast

Stock Price Forecast

The 6 analysts that cover Karyopharm Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $17.5, which forecasts a 108.83% increase in the stock price over the next year. The lowest target is $10 and the highest is $28.

Price Target: $17.5 (+108.83%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$17.5	$19	$28
Change	+19.33%	+108.83%	+126.73%	+234.13%

Analyst Ratings

The average analyst rating for Karyopharm Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	2	2	2	2	2	2
Buy	5	5	5	5	5	5
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael King Rodman & Renshaw	Rodman & Renshaw	Strong Buy Initiates $28	Strong Buy	Initiates	$28	+234.13%	Mar 10, 2026
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+79.00%	Feb 18, 2026
Yanni Souroutzidis Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Feb 5, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $30 → $19	Buy	Maintains	$30 → $19	+126.73%	Nov 4, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Hold → Strong Buy Upgrades $15	Hold → Strong Buy	Upgrades	$15	+79.00%	Oct 13, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

141.67M

from 146.07M

-3.01%

from 146.07M

Revenue Next Year

207.72M

from 141.67M

46.62%

from 141.67M

EPS This Year

-5.16

from -17.93

EPS Next Year

-4.48

from -5.16

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	209.82M	157.07M	146.03M	145.24M	146.07M	141.67M	207.72M
Revenue Growth	94.12%	-25.14%	-7.03%	-0.55%	0.57%	-3.01%	46.62%
EPS	-24.75	-30.30	-18.79	-14.00	-17.93	-5.16	-4.48
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	9	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	165.7M	364.5M
Avg	141.7M	207.7M
Low	128.6M	130.2M

Revenue Growth

Revenue Growth	2026	2027
High	13.4%	157.3%
Avg	-3.0%	46.6%
Low	-12.0%	-8.1%

EPS Forecast

EPS	2026	2027
High	-3.21	-2.64
Avg	-5.16	-4.48
Low	-8.27	-7.16

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.